Cybrexa Therapeutics is Biotechnology in United States that focus on combination therapies business. Founded in 2017. They cover business area such as developer, oncology therapeutic, antigen-independent intracellular drug delivery, novel compound, robust ip, pivotal study, highly potent drug, combination therapy, toxicity, exist anticancer agent, large, high unmet need population, physician, patient outcome, life, cancer therapeutic.
2017
( 7 years old in 2024 )
Combination Therapies
-
5 Science Park
395 Winchester Avenue
New Haven, CT 06511
United States
Private
developeroncology therapeuticantigen-independent intracellular drug deliverynovel compoundrobust ippivotal studyhighly potent drugcombination therapytoxicityexist anticancer agentlarge, high unmet need populationphysicianpatient outcomelifecancer therapeutic
* We use standard office opening hours in near Cybrexa Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Cybrexa Therapeutics is Biotechnology business from United States that founded in 2017 (7 years old in 2024), Cybrexa Therapeutics business is focusing on Combination Therapies.
Cybrexa Therapeutics headquarter office and corporate office address is located in 5 Science Park 395 Winchester Avenue New Haven, CT 06511 United States.
Cybrexa Therapeutics was founded in United States.
In 2024, Cybrexa Therapeutics is currently focus on combination therapies sector.
Above is snippet of Google Trends for "combination therapies" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Cybrexa Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
